Borderline, landed KILL. Re-check at first results.
Why:
- The FY26 profit surge rode an input-price windfall that has already reversed. Acetone, the main raw material, fell 27% in FY26 (₹81.81 to ₹59.81 per kg, T1) and the margin jump landed in the same year. By mid-2026 acetone was back above ₹120 per kg (T3), dearer than in FY25, when the company earned a 4.3% net margin against FY26's 6.7%.
- The three-year tables start in a hole the filing does not show. FY23 revenue was about ₹931 cr with ₹49 cr of profit (T2, rating-agency and registry filings); the filing's window opens at FY24's ₹877 cr and ₹18 cr, a trough year with one plant shut for months. Measured from FY23 the real record is roughly 10% a year revenue growth and a 1.5-point margin recovery, not a transformation.
- Sticky customers, but no pricing power. 93% repeat revenue and 10-16 year accounts that buy more products every year are real strengths (T1). But margins sit near the bottom of comparable makers, both key inputs are imported with no long-term contracts on either side, and new domestic rivals are entering its acetone niche this year (T1/T3).
Valuation at the band
| Floor ₹643 (T1) | Cap ₹676 (T1) | |
|---|---|---|
| Bid window | 8 to 10 September 2026 | |
| Bid lot | 22 shares (T3) | |
| Fresh shares | 1,244,168 | 1,183,432 |
| Post-issue shares | 59,244,168 | 59,183,432 |
| Market capitalisation | ₹3,809 cr | ₹4,001 cr |
| P/E | 45.8x | 48.1x |
| EV/EBITDA (reported net debt) | 28.0x | 29.3x |
| EV/EBITDA (illustrative, net of the ₹60 cr earmarked repayment) | 27.5x | 28.9x |
| Promoter and family holding after | 76.9% | 77.5% |
The filing's own peer table runs from a 17.12x P/E (Excel Industries, the closest phosphorus peer) to 206.68x, averaging 61.74x, so the band prices Prasol below that average and at nearly three times its closest peer. The price does not move the verdict either way; the six ratings judge the business, not the band.
The story
A buyer of this IPO is buying the phosphorus side of the business: 38% of revenue growing 35% a year, now supplying more than half of all growth, with a second plant at Mahad still only 44% full. The catch is that filling Mahad is worth far less than it looks — the extra tonnes sell cheaper and earn thinner margins than the average — and the acetone side, still the biggest block, grew only 9% last year.
What this business is
Prasol buys two imported feedstocks, acetone and yellow phosphorus, and turns them into more than 150 downstream chemicals sold to makers of agrochemicals, lubricant additives, paints, drugs and personal care products. It runs two plants in Maharashtra with about 98,600 tonnes of annual capacity, serves about 1,600 customers with no single one above 5% of sales, and exports a quarter of what it makes to around 56 countries.
The money is made on the spread between the imported input price and the derivative price. Two-thirds of raw material is imported, there are no long-term contracts with suppliers or most customers, and the filing itself says even domestic prices follow global prices. Revenue was ₹1,233 cr in FY26 with a ₹83 cr profit.
Easy or difficult business? Genuinely hard chemistry — hydrogenation, halogenation and high-temperature processes that need licences, safety systems and one-to-four-year customer approvals. The difficulty cuts both ways: it keeps casual rivals out, and it has cost Prasol four worker deaths since 2020 and two regulator-ordered plant closures.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 876.6 | 1,012.5 | 1,232.6 |
| Revenue growth % | n/a | 15.5 | 21.7 |
| Gross margin % | 26.1 | 28.5 | 30.7 |
| EBITDA | 60.5 | 87.8 | 139.3 |
| EBITDA margin % | 6.9 | 8.7 | 11.3 |
| PAT | 18.1 | 43.6 | 83.1 |
| PAT growth % | n/a | 140.3 | 90.8 |
Profit grew far faster than revenue in both years because the cost of goods line fell as acetone cheapened and a trough year unwound; nearly all of the margin gain sits in that one line, not in overheads shrinking with scale.
| Segment, ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Acetone-based | 411.7 | 483.3 | 526.9 |
| Acetone-based growth % | n/a | 17.4 | 9.0 |
| Phosphorus-based | 278.9 | 349.0 | 472.0 |
| Phosphorus-based growth % | n/a | 25.1 | 35.3 |
| Other specialty | 182.6 | 174.5 | 225.9 |
| Other specialty growth % | n/a | -4.4 | 29.4 |
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | The customer relationships are the real edge: 93% repeat revenue, one-to-four-year approval cycles, and named accounts that went from buying one product to buying four to nine over a decade. It is India's only isophorone maker and its largest acetone importer, and the phosphorus line is winning share. But none of it converts into pricing power: margins sit near the bottom of comparable makers, the company is a price-taker on two imported inputs with no long-term contracts on either side, the one monopoly is a small niche growing 2-3% a year, and Deepak and Haldia are building into its acetone space right now. Solid, ordinary, defensible — not good enough to own the profit pool. |
| Industry and TAM | PASS | The phosphorus pool it actually serves is large and growing about 8%; the acetone niche is small, slow, and Prasol already holds perhaps a fifth of it. |
| Financial momentum | MARGINAL | Real 36% volume growth off a real trough, but two-thirds of the margin gain was recovery plus a feedstock windfall that reversed after March 2026. |
| Risks, governance, RPTs | MARGINAL | Four deaths and two regulator closures since 2020; auditors flagged the same inventory-control gap three years running; everything disclosed, amounts small. |
| Promoter and cap table | PASS | Clean 58 million-share base with nothing convertible and nil pledges; the operating family delivered capacity and recovered a shut plant. |
| Offer structure | MARGINAL | ₹420 cr of the ₹500 cr is the family selling; the company keeps about ₹13 cr after repaying ₹60 cr of debt; no expansion is funded. |
Watch out for
- Four worker deaths since 2020 and five pending criminal complaints against the managing director. Both plants have been closed by the pollution regulator at least once; some notices recurred in 2025 after the company reported the defects fixed (T1).
- The auditors have flagged the same inventory and overhead-allocation control gap in all three years, and the finance director is the chairman's son-in-law. Nothing suggests wrong numbers, but the weak control sits exactly under the margin story (T1).
- Signs consistent with a year-end sales push: receivable days rose 16 days in FY26, the fourth quarter drew down stock at over five times the usual rate, and this is the company's second attempt to list. Not proven either way; the first results after listing will settle it (T1).
The offer
- Raising ₹500 cr: ₹80 cr fresh issue and ₹420 cr offer for sale (T1).
- For repaying ₹60 cr of borrowings, plus general corporate purposes; there is no expansion or plant object in the offer.
- Implied valuation is in the table above: ₹3,809 to ₹4,001 cr at the band.
- Promoters and family hold 89.2% before the offer, are selling roughly ₹396 cr of the ₹420 cr offer for sale, and keep about 77% after — with more selling required within listing rules to reach the 25% public minimum.
Initial assessment from the RHP, with no outside verification beyond the price band and offer dates, which come from the NSE and BSE public records, and the FY2023 figures and input-price checks noted above. Numbers carry source tiers: (T1) the filing's audited sections, (T2) exchange or registry data, (T3) the issuer-commissioned industry chapter or press, UNVERIFIED where the filing does not support them. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.